Advances in the Stem Cell Industry: The future impact of innovation, and an evaluation of the commercial landscape

Table of Contents

Executive summary

• Background
• Stem cell research and development: scope and status
• Commercial landscape
• Industry landscape

Chapter 1 - Background

• Summary

• Introduction
• The building blocks of life

• About stem cells
• Potency
• Stem cell division
• Stem cell research
  • Human ESCs

• Current status of knowledge
• Embryonic stem cells
  • Growth and identification of ESCs
  • Stimulating ESCs to differentiate
• Adult stem cells
• Cord blood stem cells
• Induced pluripotent stem cells
• Nuclear reprogramming
• Ethical and regulatory issues
  • Situation in the US
  • European regulations

Chapter 2 - Stem cell research and development: scope and status

• Summary
• Introduction

• Practical applications of stem cells
• Disease treatment
  • Amyotrophic lateral sclerosis
  • Parkinson' s disease
  • Spinal cord injury
  • Alzheimer' s disease
  • Cancer
  • Heart disease
  • Peripheral arterial disease
  • Type 1 diabetes
  • Liver failure
  • Graft-versus-host disease
• Stem cell models: applications in drug discovery
  • Screening studies
  • Toxicity studies
  • Practical benefits
  • Some skepticism remains

Chapter 3 - Commercial landscape

• Summary
• Resisting the hyperbole

• Market realities
• Cell-based therapy market
  • Autologous SC therapy
  • Allogeneic SC therapy
• Cord blood banks
• Market drivers
• Market

• Global market estimates and forecasts
• Global market by use
• Global market by country share
  • Embryo vs. adult stem cells
  • Investment opportunities
• Choosing a viable business model
  • Matching the model to the circumstance
  • Autologous therapy models
  • Allogeneic therapy models

Chapter 4 - Industry landscape

• Summary
• Introduction

• Company profiles
• Aastrom Biosciences, Inc.
  • Overview
  • Pipeline
• Advanced Cell Technology, Inc.
  • Overview
  • Pipeline
  • Collaboration
• Aldagen
  • Overview
  • Pipeline
  • Collaboration
• Angioblast Systems, Inc.
  • Overview
  • Pipeline
• Athersys, Inc.
  • Overview
  • Pipeline
  • Collaboration
  • Financials
• Bioheart, Inc.
  • Overview
  • Pipeline
• Bionet
  • Overview
  • Collaboration
• Brainstorm Cell Therapeutics
  • Overview
• Capricor, Inc.
  • Overview
  • Pipeline
  • Collaboration
• Cardio3 BioSciences SA
  • Overview
• Cellcyte Genetics
  • Overview
  • Pipeline
  • Collaboration
• Cellerix SA
  • Overview
  • Pipeline
• CellGenix Technologie Transfer
  • Overview
• Cytori Therapeutics, Inc.
  • Overview
• Entest BioMedical, Inc.
  • Overview
• ES Cell International
  • Overview
• EvoStem Finland Oy
  • Overview
• Fate Therapeutics, Inc.
  • Overview
• Genzyme
  • Collaboration
  • Financials
• Geron
  • Overview
  • Pipeline
• Healtheuniverse, Inc.
  • Overview
• Innovacell Biotechnologie AG
  • Overview
• International Stem Cell Corporation (ISCO)
  • Overview
  • Financing
• iPierian, Inc.
  • Overview
• Ixion Biotechnology, Inc.
  • Overview
• Karocell Tissue Engineering AB
  • Overview
• MedCell Bioscience Ltd
  • Overview
• MediStem, Inc.
  • Overview
  • Pipeline
• Mesoblast Limited
  • Overview
• Nephrogenix
  • Overview
• Neuralstem, Inc.
  • Overview
  • Pipeline
  • Collaboration
• OncoStem Pharma
  • Overview
• Novocell, Inc.
  • Overview
• NuVasive, Inc.
  • Overview
• Osiris Therapeutics, Inc.
  • Overview
  • Pipeline
  • Collaboration
  • Financials
• Pharmicell Europe GmbH
  • Overview
• PrimeGen Biotech
  • Overview
• Opexa Therapeutics
  • Overview
  • Financing
  • Financials
• Plureon
  • Overview
  • Pipeline
  • Collaboration
• Proteonomix, Inc.
  • Overview
• Regenerative Sciences, Inc.
  • Overview
• ReNeuron
  • Overview
  • Pipeline
• Shenzhen Beike
  • Overview
• Stematix, Inc.
  • Overview
• StemCells, Inc.
  • Overview
• Stem Cell Therapeutics
  • Overview
• Stem Cell Therapy International
  • Overview
• Stemedica Cell Technologies, Inc.
  • Overview
• Stempeutics Research Pvt. Ltd.
  • Overview
• t2cure GmbH
  • Overview
• TICEBA GmbH
  • Overview
• Tristem
  • Overview

Chapter 5 - Appendix

• Methodology
• Glossary
• Index

List of Figures

• Figure 1.1: Early embryonic development and later differentiation
• Figure 1.2: Stem cell division
• Figure 1.3: Induced pluripotent stem cells
• Figure 2.4: Stem cell opportunities in disease treatment and R&D
• Figure 3.5: Forces affecting the stem cell market
• Figure 3.6: Key challenges faced when developing autologous therapy
• Figure 4.7: Type and number of regenerative medicine organizations

List of Tables

• Table 3.1: Global stem cell market ($m), 2008-14
• Table 3.2: Potential US patient populations for cell-based therapies
• Table 3.3: Stem cell market by main uses ($m), 2008-14
• Table 3.4: Country breakdown of stem cell market ($m), 2008-14
• Table 3.5: Leading cell-based regenerative medicine products